Nicholas Piramal acquires Eli Lilly, Ranbaxy brands
ENS ECONOMIC BUREAU

MUMBAI, DEC 25: Nicholas Piramal has acquired four brands, Mucokef, Zidime and Keroxime from American multinational Eli Lilly & Company and an anti-viral Lovir from the Delhi-based Ranbaxy Laboratories. Rabo India, the Indian subsidiary of Rabobank International was the sole advisor to Eli Lilly Ranbaxy for the transaction. A press release issued by Rabo India Finance Pvt said these brands were hitherto licensed to, and were marketed by, thier joint venture company Eli Lilly Ranbaxy Ltd in India. The definitive agreements towards this end were signed recently.

Nicholas Piramal is moving to strengthen its strategic presence in the hospital sector.

Copyright © 1999 Indian Express Newspapers (Bombay) Ltd.